IL-1-话题@MedSci

#IL-1#

184篇内容 | 4453人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1508293, encodeId=982e15082939a, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, objectTitle=期刊速递丨肿瘤治疗新公式？多功能溶瘤纳米颗粒+可自我复制的IL-12 RNA=消灭肿瘤！, objectType=article, longId=199213, objectId=bdd519921302, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bdd519921302, replyNumber=0, likeNumber=34, createdTime=2020-08-13, rootId=0, userName=jjjiang0202, userId=f6cf9946833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bdd519921302, moduleTitle=期刊速递丨肿瘤治疗新公式？多功能溶瘤纳米颗粒+可自我复制的IL-12 RNA=消灭肿瘤！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bdd519921302)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1508292, encodeId=7a101508292a3, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, objectTitle=诺华IL-17A单抗Cosentyx：获欧盟批准一线治疗牛皮癣儿童患者, objectType=article, longId=198732, objectId=59fb198e32ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=59fb198e32ce, replyNumber=0, likeNumber=71, createdTime=2020-08-06, rootId=0, userName=jjjiang0202, userId=f6cf9946833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=59fb198e32ce, moduleTitle=诺华IL-17A单抗Cosentyx：获欧盟批准一线治疗牛皮癣儿童患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=59fb198e32ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1508291, encodeId=86ef15082916e, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, objectTitle=IL-12/IL-23单抗Stelara（ustekinumab），获得FDA批准治疗牛皮癣儿童患者, objectType=article, longId=198548, objectId=231019854869, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=231019854869, replyNumber=0, likeNumber=72, createdTime=2020-08-03, rootId=0, userName=jjjiang0202, userId=f6cf9946833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=231019854869, moduleTitle=IL-12/IL-23单抗Stelara（ustekinumab），获得FDA批准治疗牛皮癣儿童患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=231019854869)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1508290, encodeId=f9a8150829020, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, objectTitle=牛皮癣III期临床：礼来的IL-23单抗mirikizumab优于诺华的IL-17A单抗Cosentyx, objectType=article, longId=197732, objectId=5be919e73267, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5be919e73267, replyNumber=0, likeNumber=33, createdTime=2020-07-20, rootId=0, userName=jjjiang0202, userId=f6cf9946833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5be919e73267, moduleTitle=牛皮癣III期临床：礼来的IL-23单抗mirikizumab优于诺华的IL-17A单抗Cosentyx, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5be919e73267)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1508289, encodeId=14d61508289b5, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, objectTitle=IL-4/IL-13单抗DUPIXENT获得INESSS的积极推荐，用于治疗中度至重度特应性皮炎, objectType=article, longId=197603, objectId=36c019e60339, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36c019e60339, replyNumber=0, likeNumber=72, createdTime=2020-07-17, rootId=0, userName=jjjiang0202, userId=f6cf9946833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36c019e60339, moduleTitle=IL-4/IL-13单抗DUPIXENT获得INESSS的积极推荐，用于治疗中度至重度特应性皮炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36c019e60339)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1508288, encodeId=c6921508288f3, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, objectTitle=JCC: IL-6缺失会加剧IL-10缺乏小鼠的结肠炎并诱发全身性炎症反应, objectType=article, longId=197407, objectId=422119e407b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=422119e407b3, replyNumber=0, likeNumber=85, createdTime=2020-07-14, rootId=0, userName=jjjiang0202, userId=f6cf9946833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=422119e407b3, moduleTitle=JCC: IL-6缺失会加剧IL-10缺乏小鼠的结肠炎并诱发全身性炎症反应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=422119e407b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1508287, encodeId=547a150828e5c, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, objectTitle=Blood：IL-18和细胞毒性损伤是病毒诱导性超级炎症的相互独立又协同作用的驱动因素, objectType=article, longId=197020, objectId=0f6f19e02003, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f6f19e02003, replyNumber=0, likeNumber=108, createdTime=2020-07-05, rootId=0, userName=jjjiang0202, userId=f6cf9946833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f6f19e02003, moduleTitle=Blood：IL-18和细胞毒性损伤是病毒诱导性超级炎症的相互独立又协同作用的驱动因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f6f19e02003)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1508286, encodeId=02cb1508286fb, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, objectTitle=由于缺乏疗效，强生放弃IL-12/IL-23单抗Stelara治疗系统性红斑狼疮的三期研究, objectType=article, longId=196588, objectId=da7919658856, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=da7919658856, replyNumber=0, likeNumber=54, createdTime=2020-06-29, rootId=0, userName=jjjiang0202, userId=f6cf9946833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=da7919658856, moduleTitle=由于缺乏疗效，强生放弃IL-12/IL-23单抗Stelara治疗系统性红斑狼疮的三期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=da7919658856)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1508285, encodeId=06fd15082857b, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, objectTitle=AACR 2020：IL-15超激动剂SO-C101展现出强大的抗肿瘤作用, objectType=article, longId=196499, objectId=fcb619649997, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fcb619649997, replyNumber=0, likeNumber=63, createdTime=2020-06-27, rootId=0, userName=jjjiang0202, userId=f6cf9946833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fcb619649997, moduleTitle=AACR 2020：IL-15超激动剂SO-C101展现出强大的抗肿瘤作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fcb619649997)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1508284, encodeId=1edb1508284fe, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, objectTitle=FDA批准诺华的IL-17A单抗Cosytyx，用于治疗非放射线轴性脊柱关节炎, objectType=article, longId=196068, objectId=36e6196068e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36e6196068e4, replyNumber=0, likeNumber=72, createdTime=2020-06-19, rootId=0, userName=jjjiang0202, userId=f6cf9946833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36e6196068e4, moduleTitle=FDA批准诺华的IL-17A单抗Cosytyx，用于治疗非放射线轴性脊柱关节炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36e6196068e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1508283, encodeId=3725150828399, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, objectTitle=英国NICE首次批准靶向IL-12/IL-23的单抗Stelara，用于治疗溃疡性结肠炎, objectType=article, longId=196065, objectId=c775196065fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c775196065fc, replyNumber=0, likeNumber=0, createdTime=2020-06-19, rootId=0, userName=jjjiang0202, userId=f6cf9946833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c775196065fc, moduleTitle=英国NICE首次批准靶向IL-12/IL-23的单抗Stelara，用于治疗溃疡性结肠炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c775196065fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1508282, encodeId=62b21508282ff, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, objectTitle=AAD 2020：3期临床证实IL-17A/IL-17F单抗Bimekizumab治疗牛皮癣，优于IL-12/IL-23单抗ustekinumab, objectType=article, longId=195839, objectId=0f4c19583900, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f4c19583900, replyNumber=0, likeNumber=43, createdTime=2020-06-15, rootId=0, userName=jjjiang0202, userId=f6cf9946833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f4c19583900, moduleTitle=AAD 2020：3期临床证实IL-17A/IL-17F单抗Bimekizumab治疗牛皮癣，优于IL-12/IL-23单抗ustekinumab, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f4c19583900)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1508281, encodeId=16fa1508281e1, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, objectTitle=欧盟监管机构开始审查LEO的IL-13单抗tralokinumab，治疗特应性皮炎, objectType=article, longId=195833, objectId=7404195833c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7404195833c3, replyNumber=0, likeNumber=95, createdTime=2020-06-15, rootId=0, userName=jjjiang0202, userId=f6cf9946833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7404195833c3, moduleTitle=欧盟监管机构开始审查LEO的IL-13单抗tralokinumab，治疗特应性皮炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7404195833c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1508280, encodeId=6c4e1508280aa, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, objectTitle=诺华III期PREVENT研究：IL-17A单抗Cosentyx可持久缓解中轴性脊柱关节炎, objectType=article, longId=195329, objectId=e84519532957, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e84519532957, replyNumber=0, likeNumber=78, createdTime=2020-06-06, rootId=0, userName=jjjiang0202, userId=f6cf9946833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e84519532957, moduleTitle=诺华III期PREVENT研究：IL-17A单抗Cosentyx可持久缓解中轴性脊柱关节炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e84519532957)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1508279, encodeId=38ef15082e900, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, objectTitle=J Clin Periodontol：唾液IL-1β水平用于估计非吸烟者和吸烟者牙周炎发生概率的准确性, objectType=article, longId=195090, objectId=d51a1950908a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d51a1950908a, replyNumber=0, likeNumber=87, createdTime=2020-06-02, rootId=0, userName=jjjiang0202, userId=f6cf9946833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d51a1950908a, moduleTitle=J Clin Periodontol：唾液IL-1β水平用于估计非吸烟者和吸烟者牙周炎发生概率的准确性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d51a1950908a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1508278, encodeId=376515082e81f, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, objectTitle=Cell Death Dis：LINC01116通过IL-1β神经胶质瘤的增殖和中性粒细胞募集, objectType=article, longId=194556, objectId=cc491945568f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cc491945568f, replyNumber=0, likeNumber=56, createdTime=2020-05-23, rootId=0, userName=jjjiang0202, userId=f6cf9946833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cc491945568f, moduleTitle=Cell Death Dis：LINC01116通过IL-1β神经胶质瘤的增殖和中性粒细胞募集, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cc491945568f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1508277, encodeId=525715082e724, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, objectTitle=欧盟批准诺华的IL-17单抗Cosentyx，用于治疗非放射线轴性脊柱关节炎, objectType=article, longId=193367, objectId=384819336e00, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=384819336e00, replyNumber=0, likeNumber=65, createdTime=2020-05-03, rootId=0, userName=jjjiang0202, userId=f6cf9946833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=384819336e00, moduleTitle=欧盟批准诺华的IL-17单抗Cosentyx，用于治疗非放射线轴性脊柱关节炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=384819336e00)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1508276, encodeId=e21c15082e623, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, objectTitle=IL-6试验令人失望后，诺华将测试IL-1单抗canakinumab用于抵抗新冠COVID-19的细胞因子风暴, objectType=article, longId=193314, objectId=6b1119331457, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6b1119331457, replyNumber=0, likeNumber=56, createdTime=2020-05-03, rootId=0, userName=jjjiang0202, userId=f6cf9946833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6b1119331457, moduleTitle=IL-6试验令人失望后，诺华将测试IL-1单抗canakinumab用于抵抗新冠COVID-19的细胞因子风暴, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6b1119331457)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1508275, encodeId=a41a15082e5d3, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, objectTitle=英国NICE推荐将IL-12/IL-23单抗ustekinumab，用于治疗活动性中度至重度溃疡性结肠炎, objectType=article, longId=193135, objectId=1689193135a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1689193135a7, replyNumber=0, likeNumber=39, createdTime=2020-04-30, rootId=0, userName=jjjiang0202, userId=f6cf9946833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1689193135a7, moduleTitle=英国NICE推荐将IL-12/IL-23单抗ustekinumab，用于治疗活动性中度至重度溃疡性结肠炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1689193135a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1508274, encodeId=441915082e4be, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, objectTitle=J Periodontal Res：牙周健康和疾病患者中唾液Del-1, IL-17和LFA-1的水平分析, objectType=article, longId=192227, objectId=5c0a19222e50, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5c0a19222e50, replyNumber=0, likeNumber=72, createdTime=2020-04-15, rootId=0, userName=jjjiang0202, userId=f6cf9946833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5c0a19222e50, moduleTitle=J Periodontal Res：牙周健康和疾病患者中唾液Del-1, IL-17和LFA-1的水平分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5c0a19222e50)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

IL-1

2020-05-29

jjjiang0202 (审核中...)

前往app查看评论内容

#IL-1#

期刊速递丨肿瘤治疗新公式？多功能溶瘤纳米颗粒+可自我复制的IL-12 RNA=消灭肿瘤！

2020-08-13

jjjiang0202 (审核中...)

前往app查看评论内容

#IL-1#

诺华IL-17A单抗Cosentyx：获欧盟批准一线治疗牛皮癣儿童患者

2020-08-06

jjjiang0202 (审核中...)

前往app查看评论内容

#IL-1#

IL-12/IL-23单抗Stelara（ustekinumab），获得FDA批准治疗牛皮癣儿童患者

2020-08-03

jjjiang0202 (审核中...)

前往app查看评论内容

#IL-1#

牛皮癣III期临床：礼来的IL-23单抗mirikizumab优于诺华的IL-17A单抗Cosentyx

2020-07-20

jjjiang0202 (审核中...)

前往app查看评论内容

#IL-1#

IL-4/IL-13单抗DUPIXENT获得INESSS的积极推荐，用于治疗中度至重度特应性皮炎

2020-07-17

jjjiang0202 (审核中...)

前往app查看评论内容

#IL-1#

JCC: IL-6缺失会加剧IL-10缺乏小鼠的结肠炎并诱发全身性炎症反应

2020-07-14

jjjiang0202 (审核中...)

前往app查看评论内容

#IL-1#

Blood：IL-18和细胞毒性损伤是病毒诱导性超级炎症的相互独立又协同作用的驱动因素

2020-07-05

jjjiang0202 (审核中...)

前往app查看评论内容

#IL-1#

由于缺乏疗效，强生放弃IL-12/IL-23单抗Stelara治疗系统性红斑狼疮的三期研究

2020-06-29

jjjiang0202 (审核中...)

前往app查看评论内容

#IL-1#

AACR 2020：IL-15超激动剂SO-C101展现出强大的抗肿瘤作用

2020-06-27

jjjiang0202 (审核中...)

前往app查看评论内容

#IL-1#

FDA批准诺华的IL-17A单抗Cosytyx，用于治疗非放射线轴性脊柱关节炎

2020-06-19

jjjiang0202 (审核中...)

前往app查看评论内容

#IL-1#

英国NICE首次批准靶向IL-12/IL-23的单抗Stelara，用于治疗溃疡性结肠炎

2020-06-19

jjjiang0202 (审核中...)

前往app查看评论内容

#IL-1#

AAD 2020：3期临床证实IL-17A/IL-17F单抗Bimekizumab治疗牛皮癣，优于IL-12/IL-23单抗ustekinumab

2020-06-15

jjjiang0202 (审核中...)

前往app查看评论内容

#IL-1#

欧盟监管机构开始审查LEO的IL-13单抗tralokinumab，治疗特应性皮炎

2020-06-15

jjjiang0202 (审核中...)

前往app查看评论内容

#IL-1#

诺华III期PREVENT研究：IL-17A单抗Cosentyx可持久缓解中轴性脊柱关节炎

2020-06-06

jjjiang0202 (审核中...)

前往app查看评论内容

#IL-1#

J Clin Periodontol：唾液IL-1β水平用于估计非吸烟者和吸烟者牙周炎发生概率的准确性

2020-06-02

jjjiang0202 (审核中...)

前往app查看评论内容

#IL-1#

Cell Death Dis：LINC01116通过IL-1β神经胶质瘤的增殖和中性粒细胞募集

2020-05-23

jjjiang0202 (审核中...)

前往app查看评论内容

#IL-1#

欧盟批准诺华的IL-17单抗Cosentyx，用于治疗非放射线轴性脊柱关节炎

2020-05-03

jjjiang0202 (审核中...)

前往app查看评论内容

#IL-1#

IL-6试验令人失望后，诺华将测试IL-1单抗canakinumab用于抵抗新冠COVID-19的细胞因子风暴

2020-05-03

jjjiang0202 (审核中...)

前往app查看评论内容

#IL-1#

英国NICE推荐将IL-12/IL-23单抗ustekinumab，用于治疗活动性中度至重度溃疡性结肠炎

2020-04-30

jjjiang0202 (审核中...)

前往app查看评论内容

#IL-1#

J Periodontal Res：牙周健康和疾病患者中唾液Del-1, IL-17和LFA-1的水平分析

2020-04-15

科室
- - 订阅+
  - 更多科室
工具
服务